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Abstract: Background: G-protein-coupled bile acid receptor (TGR5), a membrane bile acid
receptor, regulates macrophage reactivity, and attenuates inflammation in different disease models.
However, the regulatory effects of TGR5 in ischemia/reperfusion (I/R)-induced kidney injury
and inflammation have not yet been extensively studied. Therefore, we hypothesize that Farnesiferol
B, a natural TGR5 agonist, could alleviate renal I/R injury by reducing inflammation and macrophage
migration through activating TGR5. Methods: Mice were treated with Farnesiferol B before I/R or
sham procedures. Renal function, pathological analysis, and inflammatory mediators were examined.
In vitro, the regulatory effects of Farnesiferol B on the Nuclear Factor kappa-light-chain-enhancer of
activated B cells (NF-κB) pathway in macrophages were investigated. Results: After I/R, Farnesiferol
B-treated mice displayed better renal function and less tubular damage. Farnesiferol B reduced
renal oxidative stress and inflammation significantly. In vitro, Farnesiferol B treatment alleviated
lipopolysaccharide (LPS)-induced macrophage migration and activation, as well as LPS-induced
NF-κB activation through TGR5. Conclusions: Farnesiferol B could protect kidney function
from I/R-induced damage by attenuating inflammation though activating TGR5 in macrophages.
Farnesiferol B might be a potent TGR5 ligand for the treatment of I/R-induced renal inflammation.
Keywords: inflammation; ischemia/reperfusion injury; Farnesiferol B; Nuclear Factor kappa-light-
chain-enhancer of activated B cells (NF-κB); G-protein-coupled bile acid receptor (TGR5)
1. Introduction
Ischemia/reperfusion (I/R) is a common complication in patients undergoing major cardiac surgery,
kidney transplantation, and those experiencing hemorrhage and dehydration [1]. Ischemia/reperfusion
injury (I/RI) after renal transplantation is a well-recognized and prevalent postoperative complication,
which has been thought as a risk factor for the loss of tubular epithelial cell function, leading to
acute kidney injury (AKI), delayed graft function, as well as acute or chronic organ rejection [2,3].
The process of renal ischemia reperfusion (RIR) is exceedingly complex, including a series of intricate
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and related events that lead to renal cell injury and ultimately give rise to cell death via apoptosis
and necrosis [4]. Even though reperfusion is critically paramount for the repair of ischemic tissue
and the survival of patients, the additional cellular damage by itself has provoked much attention,
largely due to the production of reactive oxygen species (ROS) and infiltration of neutrophils [5,6].
The mechanism and treatment of I/R on kidney injury is still under exploration. During I/R, toxic
products of kidney cells and cytokine release cause damage to renal epithelial tubular cells [7]. Besides,
several studies have suggested that I/R leads rise to neutrophil infiltration of kidney tissue and stimulates
the oxidative stress processes producing ROS [8]. Oxidative stress directly or indirectly affects all
aspects of the kidney damage by the pathway lead to apoptosis, necrosis, fibrosis, tissue damage
progression, and renal dysfunction [9]. ROS is considered as both the mediator or a signaling molecule
during acute kidney inflammatory diseases [10]. The oxidase activity is elevated soon after ischemic
injury, which is may originate from macrophages and/or neutrophils [11]. Moreover, inflammatory
cells can also induce post-hypoxic cellular damage by ROS, which in turn gives rise to tubular epithelial
cell damage or death by triggering apoptosis and necrosis pathways [12,13].
Early in a classic pharmacopoeia of traditional Chinese medicine book, Ferulae Resina is recorded
as widely used for its effects on removing stagnancy (Xiao Ji), dissolving hard mass (Hua Jia), dissipating
obstruction (San Pi), and as having anthelmintic properties (Sha Chong). Previous research reported
the isolation of Farnesiferol B, a new sesquiterpene that is highly produced in the Apiaceae family,
from the roots of Ferula [14,15]. Farnesiferol B has shown anti-plasmodial activity and anti-cytotoxicity
effects in rat skeletal fibroblasts, a L6-cell line [16]. In a recent in silico work, Farnesiferol B was
confirmed as a TGR5 agonist, also known as a G-protein-coupled bile acid receptor 1 (GPBAR1)
activator, which denotes a regulatory effect of Farnesiferol B on inflammation [17].
TGR5 is expressed in several types of cells, including hepatic non-parenchymal cells [18–20].
The renal tubular cells, and immune cells including monocytes and macrophages [21,22]. Recently,
it was demonstrated that TGR5 activation could be exploited to confer protection from diabetic
nephropathy [23]. Considering that TGR5 activation possesses anti-oxidant and anti-inflammatory
roles [23,24] in the kidney, we hypothesized that Farnesiferol B would alleviate renal I/R injury by
reducing inflammation and ROS through regulating renal tubular cells and macrophages over TGR5.
In this study, the protective effect of Farnesiferol B was examined in a mouse model of AKI
induced by I/R. We investigated the regulatory effects of Farnesiferol B on pro-inflammatory pathways
in LPS-treated macrophages.
2. Results
2.1. Farnesiferol B Protection for Kidney Damage in I/R Kidney
The overall effect of Farnesiferol B on kidney injury was first explored by histological assessment
and creatinine quantification. Haemotoxylin and Eosin (HE) staining and kidney injury marker Kim-1
(kidney injury molecule-1) immunohistochemical staining analysis results show that I/R kidneys are
characterized by tubular basal membrane rupture, nuclear infiltration, tubular vacuolization, higher
Kim-1 expression, and a higher renal tubular injury score (Figure 1A,B,E). Levels of proximal tubular
cell death and cell proliferation were assessed. In the TUNEL assay, the nuclei of TUNEL-positive
cells were stained red (Figure 1C), and the levels of cell death were indicated as the percentage of
TUNEL-positive cells (Figure 1F). TUNEL-positive cells were observed mainly in the tubular area of
the renal cortex. I/R group displayed more TUNEL-positive cells that the sham group (Figure 1C(b)
vs. (a)). PCNA expression was observed in proliferating cell nuclei, and was significantly increased in
AKI compared with the sham group (Figure 1D,G). Serum creatinine levels in I/R mice were significantly
elevated in comparison to sham-operated mice (Figure 1H). The treatment with Farnesiferol B prior
to I/R decreased serum creatinine level, attenuating the I/R-induced kidney injury (Figure 1A,C,H).
However, Farnesiferol B treatment did not change the I/R-induced cell proliferation (Figure 1D(c)
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vs. (b)). The above results suggest that, in general, Farnesiferol B treatment protects against the kidney
damage caused by I/R.
Figure 1. Farnesiferol B protects kidney from I/R-induced kidney damage. Representative images showing
(A) Haemotoxylin and Eosin (HE) staining and (B) Kim1, (C) TUNEL, (D) PCNA immunostaining on renal
sections from (a) sham, (b) I/R, (c) I/R + Farnesiferol B and (d) sham + Farnesiferol B groups (scale bar
50 µm). Quantitative analysis of (E) tubular injury scores, (F) TUNEL staining, (G) PCNA staining, and (H)
serum creatinine from different groups. n = 6 mice/group. Data are means ± SD, one-way ANOVA with
Bonferroni’s test. * p < 0.05.
2.2. Farnesiferol B Reduces Oxidative Stress and Lipid Oxidative Signaling Pathways in I/R Kidney
I/R is often associated with oxidative stress, with existing evidence suggesting that oxidative
stress is a paramount contributor in causing kidney damage [25]. Therefore, the effect of Farnesiferol B
on oxidative stress in the kidney after I/R was evaluated. Immunohistochemical staining for NGAL
neutrophil gelatinase-associated lipocalin (NGAL), an oxidative stress risk factor, showed that I/R may
induced significant increases of oxidative stress in I/R kidneys (Figure 2A(b),B). The level of NGAL was
reduced in mice treated with Farnesiferol B (Figure 2A(c),B). The potential mechanisms involved in
the inhibitory effects of Farnesiferol B on I/R-induced oxidative stress were investigated. The I/R greatly
increased the oxidative stress production and impaired antioxidant capacity in the injured kidney
(Figure 2C–E). Farnesiferol B administration significantly diminished oxidative stress in the urine
of injured group, namely H2O2 (hydrogen peroxide). Treatment with Farnesiferol B significantly
increased the expression of Nrf2 and its downstream HO-1 (Figure 2D,E).
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Figure 2. Farnesiferol B reduces oxidative stress in ischemia/reperfusion (I/R) kidney. (A) Representative
images of immunostaining for NGAL on renal sections from (a) sham, (b) I/R, (c) I/R + Farnesiferol B
and (d) sham + Farnesiferol B groups (scale bar 50 µm). (B) urinary neutrophil gelatinase-associated
lipocalin (NGAL), (C) urinary H2O2, and kidney mRNA levels of (D) Nrf2 and (E) HO-1 were
analyzed. n = 6 mice/group. Data are means ± SD, one-way ANOVA with Bonferroni’s test. * p < 0.05.
(F) Representative images of immunostaining for 4-HNE on renal sections from (a) sham, (b) I/R, (c) I/R
+ Farnesiferol B and (d) sham + Farnesiferol B groups (scale bar 50 µm). (G) kidney malondialdehyde
(MDA), (H) kidney GSH, and kidney mRNA levels of (I) Gpx4 were analyzed. n = 6 mice/group.
Data are means ± SD, one-way ANOVA with Bonferroni’s test. * p < 0.05.
Reactive oxygen species accumulation can lead to lipid peroxidation and ferroptosis,
a kind of regulated cell death [26]. The lipid peroxidation marker, 4-HNE (4-hydroxynonenal)
and MDA (malondialdehyde), and markers related to ferroptosis were examined. The results show
that 4-HNE and MDA levels were induced and GSH (glutathione) levels were reduced in the injured
kidney (Figure 2F–H). Farnesiferol B administration reduced kidney lipid peroxidation and induced
GSH level in the renal tissue homogenate. Furthermore, mRNA expression of Gpx4, the key ferroptosis
regulator, was examined (Figure 2I). Gpx4 mRNA level was significantly down-regulated after I/R
injury, whereas the expression seemed to be increased by Farnesiferol B treatment (not significantly).
Taken together, the results indicated that anti-lipid peroxidation effects seen in Farnesiferol B treatment
group could be an indirect result of its regulation on antioxidant pathways.
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2.3. Farnesiferol B Protectes Kidney from I/R-Induced Inflammation and Inhibits NF-κB Signaling Pathway
The other oxidative stress-producer is the inflammatory cell such as monocytes and macrophages,
which infiltrate into tissue, especially during acute inflammation [27]. Next, we analyzed the degree
of kidney inflammation. I/R increased the positive stainings of macrophages and neutrophils in
the kidney (Figure 3A–D). I/R also induced levels of TNFα and MCP-1 in mouse serum and kidney,
as well as the proinflammatory mediator LTB4 in the kidney (Figure 3E–I). The number of macrophages
and neutrophils, as well as the serum and kidney levels of TNFα, MCP-1, and LTB4 were significantly
reduced by Farnesiferol B treatment (Figure 3E–I). Inflammation-related genes expressed in the kidney
were also measured. Quantitative analysis showed that I/R stimulated the expression of kidney TNFα,
IL-6, and Icam mRNA levels, while levels of these mRNA decreased under treatment with Farnesiferol
B (Figure 3J–L). The evidence presented here suggests a positive role of Farnesiferol B in attenuating
renal inflammation.
Figure 3. Farnesiferol B protects kidney from I/R-induced inflammation. (A) Representative images
and (B) the quantitative analysis of positive immunostaining for macrophages on renal sections from
(a) sham, (b) I/R, (c) I/R + Farnesiferol B, and (d) sham + Farnesiferol B groups (scale bar 50µm).
(C) Representative images and (D) the quantitative analysis of positive immunostaining for neutrophils
on renal sections from (a) sham, (b) I/R, (c) I/R + Farnesiferol B, and (d) sham + Farnesiferol B groups
(scale bar 50 µm). Levels of (E) serum TNFα, (F) kidney TNFα, (G) serum MCP-1, (H) kidney MCP-1,
(I) kidney LTB4, (J) kidney TNFα mRNA, (K) kidney IL-6 mRNA, and (L) kidney Icam mRNA from
different treatment groups. n = 6 mice/group. Data are means ± SD, one-way ANOVA with Bonferroni’s
test. * p < 0.05.
NF-κB signaling pathway is one of the key inflammatory pathways during AKI. To examine
the inhibitory effects of Farnesiferol B on I/R-induced inflammation, p65 levels from different treatment
groups were evaluated. I/R induced increased tubulointerstitial staining of p65 in the kidney sections
(Figure 4A(b)) and p65 translocation in the nuclei (Figure 4B). The I/R+Farnesiferol B group showed
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reduced levels of p65 immunostaining in kidney sections as well as nuclei translocation, indicating
that part of anti-inflammatory effect is reacted on inflammatory cells.
Figure 4. Farnesiferol B inhibits NF-κB signaling pathway in I/R kidney. (A) Representative images
showing immunostaining of p65 on renal sections from (a) sham, (b) I/R, (c) I/R + Farnesiferol B and (d)
sham + Farnesiferol B groups (scale bar 50 µm). (B) Representative immunoblotting image of nuclear
protein for NF-κB p65 expression in kidney tissue. PARP-1 protein is used as the loading control.
2.4. Farnesiferol B Inhibits the Activity of Inflammatory Cells by Activating TGR5
To examine the direct effect of Farnesiferol B on macrophages, we conducted in vitro experiments
using the J774 cell line. J774 macrophages were treated with LPS and/or Farnesiferol B and migration
ability in a transwell system was monitored as a proxy for infiltration capability. Representative images
show that migration induced by LPS was abolished by co-incubation with Farnesiferol B (Figure 5A).
LPS-induced migration was associated with higher mRNA expression levels of TNFα, Ccl2, Ccl3 in
macrophages, compared with that from the untreated cells. Treatment with Farnesiferol B lowered
mRNA expression of these inflammatory cytokines significantly (Figure 5B–D).
Farnesiferol B was previously reported to be a TGR5 agonist, which can inhibit macrophage infiltration
through inhibiting NF-κB activation [28]. Based on this, we speculated that the anti-inflammatory effect
of Farnesiferol B may be related to its ability to activate TGR5. Therefore, we evaluated the regulatory
effect of Farnesiferol B on LPS-induced NF-κB activation in J774 macrophages. Immunoblotting of nuclear
protein for NF-κB p65 indicated an LPS-induced nuclear translocation in J774 macrophages (Figure 5E).
Similar to INT777, a known TGR5 agonist, Farnesiferol B also significantly reduced p65 translocation
in a dose-dependent way (Figure 5E). PARP-1 was stably expressed between groups as a nucleoprotein
control (Figure 5E). An NF-κB binding assay also revealed that LPS-induced NF-κB binding activity
was blocked by Farnesiferol B or INT777 co-incubation (Figure 5F), which was consistent with previous
publications [29].
In order to further verify the target of Farnesiferol B in macrophages, RAW264.7 cells, which do
not express TGR5 [30], were exposed to LPS with and without Farnesiferol B. As shown in Figure 6,
Farnesiferol B could not inhibit LPS-induced cell migration, suggesting that Farnesiferol B suppresses
LPS-mediated macrophage migration by activating TGR5. Benzoxathiole derivative (BOT), an NF-κB
inhibitor, was used as a positive control to block LPS-induced migration (Figure 6c). Taken together,
Farnesiferol B inhibits the LPS-induced NF-κB pathway by activating TGR5.
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Figure 5. Farnesiferol B inhibits the activity of inflammatory cells by activating TGR5. (A) Representative
images of J774 cells seeded in 3-µm pore polycarbonate membrane and stained with crystal violet for
migration analysis (scale bar 100 µm) after treatment with (a) PBS, (b) LPS, (c) LPS+Farnesiferol B, or (d)
PBS+Farnesiferol B. Level of mRNA for (B) TNFα, (C) Ccl2 and (D) Ccl3 with different treatments.
(E) Representative immunoblotting image of nuclear protein for NF-κB p65 expression. J774 cells
were treated with 100 ng/mL LPS with or without co-incubation with Farnesiferol B at 5 µM, 10 µM
and 20 µM, or INT777 for 2 h. (F) NF-κB DNA binding activity. Data are means ± SD of at least three
independent experiments, one-way ANOVA with Bonferroni’s test. * p < 0.05.
Figure 6. Farnesiferol does not inhibit migration of inflammatory cells not expressing TGR5.
Representative images of RAW 264.7 macrophages seeded in 3-µm pore polycarbonate membrane
with different treatment for 2 h, and stained with crystal violet for migration assay (scale bar 100 µm).
Cells were treated with (a) 100 ng/mL LPS, (b) LPS with 20 µM Farnesiferol co-incubation, and (c) LPS
with a NF-κB inhibitor, benzoxathiole derivative (BOT).
3. Discussion
In the current study, our results point out that Farnesiferol B treatment play a beneficial role in
renal I/R injury. Compared with I/R treated mice, Farnesiferol B-treated mice showed lower score
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of renal injury, while significantly decreased levels of histological tubular injury, oxidative stress,
and inflammation (Figure 7). In line with and based on our experiments in mice, the in vitro analysis
show that Farnesiferol B reduces LPS-induced macrophage migration. Moreover, Farnesiferol B can
inhibit NF-κB nuclear translocation through activating TGR5 in macrophages. Thus, Farnesiferol B
might represent a novel natural compound against I/R-induced kidney damage.
Figure 7. Model of the Farnesiferol B-mediated protection against ischemia/reperfusion-induced AKI.
I/R induces ROS generation that causes tubular cell damage (shown in purple-blue). In parallel,
inflammatory cell infiltration (shown in red) also promotes oxidative stress and post-hypoxic kidney
damage after I/R. Farnesiferol B-mediated TGR5 activation induces the antioxidant Nrf2 pathway
and inhibits the proinflammatory NF-κB signaling pathway, which in turn protects the kidney from
tubular damage and inflammation.
Ischaemia-reperfusion (I/R) injury is the main cause of AKI under common clinical conditions [31,32].
Nowadays, the pathogenesis of AKI is characterized by renal tubular damage, inflammation, and vascular
dysfunction [33,34]. In vivo experiment, we examined the kidney of AKI mice and found that Farnesiferol
B effectively reduced the regulated cell death and oxidative stress. Although it was hard to identify
the exact type of cell death, both results of TUNEL assay and ferroptosis marker Gxp4 showed that
Farnesiferol B have protective effects on tubular cell damage during AKI. NGAL is an early biomarker
of AKI which is produced in the distal nephron and its synthesis is upregulated in response to kidney
injury [35]. Recent evidence demonstrates that high NGAL level is a risk factor for oxidative stress in
patients [36]. In our case, I/R increased highly expression of NGAL in mice. Furthermore, Farnesiferol B
reduced the NGAL level both in kidney and in urine, as well as the other oxidative stress marker MDA.
Furthermore, with treatment of Farnesiferol B, GSH levels was increased and Nrf2 and HO-1 expression
were restored in the I/R injured kidney, while at the same time, reduced oxidative stress (H2O2) and lipid
peroxidation (4-HNE and MDA). These data indicated that antioxidant related pathways may be
regulated by Farnesiferol B-TGR5 signaling pathway. Nrf2 and its target gene, HO-1, has generally been
considered to be an adaptive cellular response to oxidative stress [26]. Recently, Nrf2/HO-1 has also been
shown to be protective in AKI and diabetic nephropathy [37–39]. It has been reported that treatment
with either FXR/TGR5 dual agonist INT-767 or TGR5 specific agonist INT-777 could prevent diabetic
nephropathy through inducing Nrf2-mediated antioxidant generation, and reducing renal expression of
oxidative stress [23,40]. We have seen similar effects in the I/R-induced mouse AKI model with treatment
with FXR/TGR5 dual agonist [25]. In the study, treatment with 6alpha-ethyl-chenodeoxycholic acid
(6-ECDCA), a potent dual FXR/TGR5 agonist [41], significantly improved Nrf2-mediated antioxidant
capacity. Silencing of Nrf2 blocked the antioxidant effect of 6-ECDCA in proximal tubule cells exposed
to hypoxia. Based on these findings, TGR5 could be a potent target to induce antioxidant pathways.
However, to identify the renal signaling pathways regulated by FXR and TGR5 respectively and specify
the regulatory effects of TGR5 on antioxidant pathways need to be further studied.
Renal inflammation after I/R is directly related to monocyte infiltration and macrophage
activation [25,42]. TGR5, also called GPBAR1 or GPR131, is a bile acid–responsive G protein-coupled
receptor, which plays a crucial role in protection against diet-induced diabetes through different cellular
mechanisms [43]. The role of TGF5 activation in modulating inflammatory pathways was confirmed
in experiments on mice and immune cells [21,28]. Recent evidence suggests that activation of TGR5
regulates inflammatory cell signaling pathways such as NF-κB, AKT and extracellular signal-regulated
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kinase (ERK) [44,45]. Macrophages play a pivotal role in kidney injury, inflammation, and fibrosis [46].
In the present study, we can clearly notice that, after I/R, the mice shown an increased inflammation level
on renal tissue (e.g., the infiltration of macrophages and neutrophils in Figure 3 and high expression of
p65 in Figure 5), as well as high level of proinflammatory factors (TNFα, MCP-1, IL-6) both in serum
and kidney tissue. While the treatment with Farnesiferol B demonstrated a critical anti-inflammatory
effects by reducing those inflammatory factors or NF-κB activation. However, NF-κB signaling can be
activated in all cell types during AKI, thereby immunostaining or immunoblotting providing only
limited information about cell-specific NF-κB functions in the kidney during AKI [47]. Therefore,
we employed the in vitro experiments. Our results shown that Farnesiferol B effectively inhibited
the expression of inflammatory cytokines, such as MCP-1, LTB4, and TNFα. Farnesiferol B inhibited
LPS-induced NF-κB activation and decreased p65 translocation in J774 macrophages, possessing
similar effects as other TGR5 agonists [40]. Moreover, the anti-inflammatory effect of Farnesiferol
B was blocked in RAW264.7 cells, which do not express TGR5 [21,30]. Taken together, these results
indicate that Farnesiferol B inhibits LPS-induced NF-κB activation through activating TGR5, which is
consistent with previous predictive results [17].
Ferula species from the family Apiaceae are rich sources of biologically active natural products
including sesquiterpene coumarins (SCs) and sesquiterpenes [48]. Some studies have shown that SCs
are able to enhance the cytotoxicity of anticancer compounds [49]. Recently Kasaian et al. showed
enhancement of doxorubicin cytotoxicity in MCF-7/Adr cells (doxorubicin resistant derivatives of
MCF-7 cells overexpressing P-gp) when combined with non-toxic concentrations of farnesiferols,
proving the significant activity of Farnesiferol B on multi-drug resistant cells [50]. Previous studies
show that sesquiterpene coumarins and their derivative from Ferula fukanensis reduces IL-6 and TNFα,
while inducing nitric oxide synthase in RAW264.7 cells, possessing inhibitory effects on LPS and IFN-γ
induced pro-inflammatory cytokine release and nitric oxide production [51,52]. A recent study also
showed the anti-inflammatory effect of Ferula szowitsiana in vitro, which indicates that Farnesiferol B
might inhibit neuroinflammation via reducing the generation of inflammatory cytokines [53]. In this
study, we show the active effect of Farnesiferol B on TGR5, which suppresses the NF-κB p65 binding
activity and inhibits macrophage migration.
4. Materials and Methods
4.1. Animals Study Approval and Tissue Samples
All animal experiments conformed to both Swiss and Chinese animal protection laws and were
approved (May, 2015) by the Scientific Animal Study Committee of Shandong University, Jinan, China
(study number 2015064).
Six-week-old female C57/BJ mice were randomly assigned to I/R or sham procedures. They were
divided into four groups with six animals each: sham, I/R, I/R + Farnesiferol B and sham + Farnesiferol B.
AKI was induced by unilateral nephrectomy and contralateral ischemia and reperfusion, as previously
described [25]. For Farnesiferol B treatment, mice were injected intraperitoneally (i.p.) with Farnesiferol
B (10 mg/kg, Golexir Pars Co., Mashhad, Iran) 2 h before the procedure. All mice were killed under
anesthesia 24 h after surgery. Kidneys were harvested for further analysis.
4.2. Measurements in Serum, Urine, and Kidney Samples
Urinary H2O2 and NGAL levels were measured in the resulting urine samples with the Amplex
Red H2O2 assay kit (A12214, Invitrogen, Carlsbad, CA, USA) and Mouse Lipocalin-2/NGAL ELISA Kit
(ab119601, Abcam, Cambridge, UK). Serum creatinine, MCP-1, TNFα, and LTB4 levels were measured
with a creatinine assay kit (ab65340, Abcam, Cambridge, UK), Mouse MCP1 ELISA Kit (ab100721,
Abcam), Mouse TNF alpha ELISA Kit (ab46105, Abcam), and LTB4 Parameter Assay Kit (KGE006B;
R&D Systems, Minneapolis, MN, USA), respectively. Kidney malondialdehyde (MDA) levels were
measured by a Lipid Peroxidation (MDA) Assay Kit (ab118970, Abcam).
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4.3. Renal Pathological Assessments and Immunostaining
Tissue sections were stained with hematoxylin and eosin (HE) using standard protocols.
TUNEL staining was performed with an ApopTag kit (Millipore, Billerica, MA, USA) based on
the manufacturer’s instructions. The antibodies for immunohistochemistry used in this study were
those against Kim-1 (ab78494, Abcam), 4-hydroxynonenal (4-HNE, ab46545, Abcam), neutrophil
gelatinase-associated lipocalin (NGAL, ab63929, Abcam), Ly-6B (NBP2-13077), NFκB p65 (sc-372, Santa
Cruz, CA, USA), and MAC387 (ab22506, Abcam). Sections were treated with the Envision+ DAB kit
(Dako, Basel, Switzerland) according to the manufacturer’s instructions.
4.4. Cell Culture and Migration Assay
J774 cells were grown in Dulbecco’s modified Eagle’s medium and RAW264.7 macrophages
were maintained in RPMI 1640 medium. Both cell culture media were supplemented with 10% FCS,
100 U/mL penicillin, and 100 mg/mL streptomycin. Cells were cultured at 37 ◦C in a humidified
atmosphere with 5% CO2.
For LPS treatment, J774 or RAW cells were treated with 100 ng/mL LPS with or without
co-incubation of 20 µM Farnesiferol B for 2 h. Afterwards, RNA and protein were extracted for further
analysis. For the migration assay, cells were seeded in 3-µm pore polycarbonate membrane inserts
(Costar Corning, Darmstadt, Germany) on 12-well plates and treated with 100 ng/mL LPS (L3254,
Sigma, St. Louis, MO, USA) or 20 µM Farnesiferol for 2 h at 37 ◦C. The inserts were washed, fixed,
and stained with crystal violet for analysis.
4.5. NF-κB DNA Binding Assay
The assay was performed with a NF-κB p65 Transcription Factor Assay kit (ab133112, Abcam). Briefly,
nuclear extracts from cells were incubated with a double stranded DNA sequence containing the NF-κB
response element overnight. After washing, an NF-κB antibody was added and incubated for 1 h.
Then an HRP-conjugated secondary antibody was added for 1 h and washed twice. After incubation with
developing solution for 30 min, stop solution was added and the results were analyzed with a microplate
reader (Glomax, Promega, Madison, WI, USA).
4.6. Isolation of RNA from Kidney Tissue and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was prepared using Trizol (Invitrogen, Carlsbad, CA, USA). The mRNA was quantified based
on absorbance at 260 nm. After DNAse (Promega) treatment, 2 µg total RNA was reverse transcribed using
oligo-dT priming and Superscript II (Invitrogen). First-strand complementary DNA was used as the template
for real-time polymerase chain reaction analysis with TaqMan master mix and primers (Life Technologies,
Carlsbad, CA, USA). Primers used were TNFα (No. Mm00443258-m1), Icam1 (No. Mm00516023_m1),
IL-6 (No. Mm00446190_m1), Ccl2 (No. Mm00441242_m1), Ccl3 (No. Mm00441259_g1), Gpx4
(No. Mm00515041_m1), Nrf2 (No. Mm00477784_m1), HO-1 (No. Mm00516005_m1). Transcript levels,
determined in two independent complementary DNA preparations, were calculated and expressed relative to
levels of RNA for the housekeeping gene beta-actin (No. Mm00607939-s1) or GAPDH (No. Mm99999915-g1).
4.7. Western Blotting
Protein lysates (20 µg protein) from cells nuclear were separated by SDS-PAGE and blotted on
polyvinylidene difluoride membranes (Millipore, Burlingtob, MA, USA). The membranes were
incubated overnight at 4 ◦C with the respective primary antibodies and secondary antibodies
accordingly. Staining was then developed using the ECL Plus detection system (Amersham Biosciences,
Little Chalfont, UK). The antibodies used were anti-p65 (sc-372, Santa Cruz, Recife, Pernambuco)
and PARP-1 (AV33754, Sigma-Aldrich).
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4.8. Statistics
Data are expressed as means ± SD. For data relating to baseline characteristics and histological
analysis, groups were compared by one-way ANOVA followed by Bonferroni’s test. Statistical analyses
were performed using GraphPad software (GraphPad Software Inc., San Diego, CA, USA).
5. Conclusions
In vivo, the present study clearly demonstrates that Farnesiferol B protects kidney from I/R-induced
damage by reducing oxidative stress and inflammation. In vitro, Farnesiferol B ameliorates macrophage
migration by activating TGR5.
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